BioMarin Pharmaceutical Inc: Unternehmensprofil, Finanzberichte & Marktperformance

mehr Informationen über BioMarin Pharmaceutical Inc Unternehmen

BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company, which is engaged in developing and commercializing therapies that address the root cause of genetic conditions. BioMarin's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Voxzogo is a once daily injection analog of C-type Natriuretic Peptide (CNP) for the treatment of achondroplasia. Brineura is a recombinant human tripeptidyl peptidase 1 (TPP1) for the treatment of patients with CLN2, a form of Batten disease.

BioMarin Pharmaceutical Inc Informationen



BörsenkürzelBMRN

Name des UnternehmensBioMarin Pharmaceutical Inc

IPO-datumJul 23, 1999

CEOMr. Alexander Hardy

Anzahl der mitarbeiter3040

WertpapierartOrdinary Share

GeschäftsjahresendeJul 23

Addresse770 Lindaro Street

StadtSAN RAFAEL

BörseNASDAQ Global Select Consolidated

LandUnited States of America

Postleitzahl94901

Telefon14155066700

Websitehttps://www.biomarin.com/

BörsenkürzelBMRN

IPO-datumJul 23, 1999

CEOMr. Alexander Hardy

Führungskräfte von BioMarin Pharmaceutical Inc



Name

Name/Position

Position

Aktienbesitz

Veränderung

Mr. Richard A. (Randy) Meier

Non-Executive Independent Chairman of the Board

120.34K

+5.85%

Mr. Alexander Hardy

President, Chief Executive Officer, Director

62.99K

-53.04%

Dr. Gregory R Friberg, M.D.

Executive Vice President, Chief Research & Development Officer

43.51K

-7.06%

Mr. Robert J. (Bob) Hombach, CPA

Independent Director

37.15K

+21.80%

Ms. Cristin Hubbard

Executive Vice President, Chief Commercial Officer

30.55K

-7.36%

Dr. Maykin Ho, Ph.D.

Independent Director

23.29K

+39.97%

Dr. Athena M. Countouriotis, M.D.

Independent Director

8.83K

+305.05%

Ms. Barbara W. Bodem

Independent Director

8.83K

+305.05%

Ms. Elizabeth Mckey Anderson

Independent Director

--

Mr. Timothy Walbert

Independent Director

--

Name

Name/Position

Position

Aktienbesitz

Veränderung

Mr. Richard A. (Randy) Meier

Non-Executive Independent Chairman of the Board

120.34K

+5.85%

Mr. Alexander Hardy

President, Chief Executive Officer, Director

62.99K

-53.04%

Dr. Gregory R Friberg, M.D.

Executive Vice President, Chief Research & Development Officer

43.51K

-7.06%

Mr. Robert J. (Bob) Hombach, CPA

Independent Director

37.15K

+21.80%

Ms. Cristin Hubbard

Executive Vice President, Chief Commercial Officer

30.55K

-7.36%

Dr. Maykin Ho, Ph.D.

Independent Director

23.29K

+39.97%

Umsatzaufteilung

Währung: USDAktualisiert: Mon, Oct 6

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

Nach GeschäftsbereichUSD

Name

Umsatz

Anteil

Voxzogo

221.39M

27.23%

Vimizim

215.42M

26.50%

Naglazyme

128.87M

15.85%

Palynziq

105.94M

13.03%

Aldurazyme

56.44M

6.94%

Andere

84.92M

10.45%

Nach RegionUSD

Name

Umsatz

Anteil

United States

272.55M

33.53%

Europe

243.14M

29.91%

Rest of the world

142.74M

17.56%

Latin America

98.12M

12.07%

ALDURAZYME net product revenues marked by Sanofi

56.44M

6.94%

Nach Geschäftsbereich

Nach Region

Nach GeschäftsbereichUSD

Name

Umsatz

Anteil

Voxzogo

221.39M

27.23%

Vimizim

215.42M

26.50%

Naglazyme

128.87M

15.85%

Palynziq

105.94M

13.03%

Aldurazyme

56.44M

6.94%

Andere

84.92M

10.45%

Aktionärsstatistik

Aktualisiert: Sat, Aug 16

Aktionäre

Aktionärstypen

Aktionäre

Anteil

The Vanguard Group, Inc.

9.84%

BlackRock Institutional Trust Company, N.A.

9.39%

PRIMECAP Management Company

8.21%

Dodge & Cox

7.86%

Viking Global Investors LP

6.40%

Andere

58.30%

Aktionäre

Anteil

The Vanguard Group, Inc.

9.84%

BlackRock Institutional Trust Company, N.A.

9.39%

PRIMECAP Management Company

8.21%

Dodge & Cox

7.86%

Viking Global Investors LP

6.40%

Andere

58.30%

Aktionärstypen

Aktionäre

Anteil

Investment Advisor

43.91%

Investment Advisor/Hedge Fund

40.30%

Hedge Fund

7.65%

Pension Fund

3.13%

Research Firm

1.58%

Sovereign Wealth Fund

1.23%

Bank and Trust

1.14%

Individual Investor

0.75%

Venture Capital

0.34%

Institutionelle Beteiligung



Aktualisiert: Wed, Oct 1

Berichtszeitraum

Anzahl der Institutionen

Gehaltenen Aktien

Anteil

Veränderung

2025Q3

1304

191.42M

99.64%

-19.19M

2025Q2

1333

195.10M

101.61%

-16.01M

2025Q1

1355

191.53M

99.87%

-20.72M

2024Q4

1336

190.53M

99.88%

-17.50M

2024Q3

1308

188.26M

98.81%

-22.17M

2024Q2

1293

192.58M

101.18%

-14.21M

2024Q1

1278

194.24M

102.38%

-11.23M

2023Q4

1294

193.16M

102.42%

-3.22M

2023Q3

1275

188.66M

100.18%

-4.68M

2023Q2

1283

185.80M

98.76%

-8.08M

Aktionärsaktivitäten



Name

Gehaltenen Aktien

Anteil

Veränderung

Änderung%

Datum

The Vanguard Group, Inc.

18.91M

9.85%

-8.07K

-0.04%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

18.04M

9.39%

-79.52K

-0.44%

Jun 30, 2025

PRIMECAP Management Company

15.77M

8.21%

-2.00M

-11.26%

Jun 30, 2025

Dodge & Cox

15.11M

7.87%

+153.07K

+1.02%

Jun 30, 2025

Viking Global Investors LP

12.29M

6.4%

+1.49M

+13.78%

Jun 30, 2025

State Street Investment Management (US)

8.85M

4.61%

+384.66K

+4.55%

Jun 30, 2025

AQR Capital Management, LLC

5.58M

2.91%

+2.65M

+90.74%

Jun 30, 2025

Geode Capital Management, L.L.C.

3.47M

1.81%

+43.19K

+1.26%

Jun 30, 2025

Millennium Management LLC

2.83M

1.48%

+2.16M

+319.74%

Jun 30, 2025

Rothschild & Co Asset Management Europe SCS

1.97M

1.03%

-20.00

-0.00%

Aug 31, 2025

Verbundene ETFs



Aktualisiert: Mon, Oct 6

Name

Anteil

Invesco Biotechnology & Genome ETF

4.74%

Global X Genomics & Biotechnology ETF

3.43%

First Trust NYSE Arca Biotechnology Index Fund

3.25%

Goldman Sachs Future Health Care Equity ETF

2.85%

SPDR S&P Biotech ETF

2.37%

WealthTrust DBS Long Term Growth ETF

2.11%

Alger Russell Innovation ETF

1.9%

First Trust Health Care Alphadex Fund

1.82%

Pacer Lunt MidCap Multi-Factor Alternator ETF

1.71%

Virtus LifeSci Biotech Products ETF

1.69%

Invesco Biotechnology & Genome ETF

Anteil4.74%

Global X Genomics & Biotechnology ETF

Anteil3.43%

First Trust NYSE Arca Biotechnology Index Fund

Anteil3.25%

Goldman Sachs Future Health Care Equity ETF

Anteil2.85%

SPDR S&P Biotech ETF

Anteil2.37%

WealthTrust DBS Long Term Growth ETF

Anteil2.11%

Alger Russell Innovation ETF

Anteil1.9%

First Trust Health Care Alphadex Fund

Anteil1.82%

Pacer Lunt MidCap Multi-Factor Alternator ETF

Anteil1.71%

Virtus LifeSci Biotech Products ETF

Anteil1.69%

Dividende



In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.

Datum

Dividende

Stichtag für die Aktienregistrierung

Zahltag

Ex-Dividendentag

Keine Daten

Aktien-Split



Datum

Art

Verhältnis

Keine Daten

Datum

Art

Verhältnis

Keine Daten